2020
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2008
Systolic Function as a Predictor of Mortality and Quality of Life in Long‐term Survivors with Heart Failure
McNamara R, Austin B, Wang Y, Smith G, Vaccarine V, Krumholz H. Systolic Function as a Predictor of Mortality and Quality of Life in Long‐term Survivors with Heart Failure. Clinical Cardiology 2008, 31: 119-124. PMID: 18383045, PMCID: PMC6653267, DOI: 10.1002/clc.20118.Peer-Reviewed Original ResearchConceptsQuality of lifeEjection fractionHeart failureLong-term survivorsFunctional declineSystolic functionKansas City Cardiomyopathy Questionnaire scoreModest survival advantageReduced ejection fractionDaily living scoreDisease-related qualityPredictors of mortalityHeart failure patientsClinical summary scoreLong-term survivalHigh mortality rateKCCQ scoresRenal insufficiencyFailure patientsLiving scoreDiabetes mellitusOverall mortalityPrimary outcomeLimitation scoresQOL scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply